Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.

Abstract

Background: Thyroid dysfunction is among the most common adverse effects during anti-programmed cell death 1 (PD-1) immunotherapy, and alongside correlations with elevated anti-thyroid antibodies (ATAb), studies have found correlations with survival. However, the exact relations remain to be clarified. We, therefore, aimed at clarifying the relationship between thyroid dysfunction, ATAbs, and survival in anti-PD-1 treated cancer patients. Methods: We included 168 patients with nonsmall-cell lung carcinoma, renal cell carcinoma, and metastatic melanoma treated with nivolumab or pembrolizumab. Thyrotropin and free T4 (fT4) levels were measured before each anti-PD-1 infusion. ATAb levels (anti-thyroid peroxidase [TPO] and anti-thyroglobulin [Tg]) were measured at baseline and after two months of treatment. Although the vast majority of patients had detectable levels of ATABs, only a few patients had positive ATAbs when using conventional cut-offs. To study the consequences of detectable ATABs, the cut-off levels were a priori set at the median concentrations at baseline in the study population. Tumor progression was classified according to RECIST v1.1. Results: Patients who acquired overt thyroid dysfunction during treatment had significantly higher overall survival (OS) (hazard ratio [HR] = 0.18 confidence interval [CI: 0.04-0.76]; p = 0.020) and progression-free survival (PFS) (HR = 0.39 [0.15-0.998]; p = 0.050) than patients without thyroid dysfunction with 1-year OS rates of 94% vs. 59% and 1-year PFS rates of 64% vs. 34%. During treatment, patients with ATAb levels above the median had a higher OS (HR = 0.39 [0.21-0.72]; p = 0.003) and PFS (HR = 0.52 [0.33-0.81]; p = 0.004) than patients with ATAb levels below the median, with 1-year OS rates of 83% vs. 49% and PFS rates of 54% vs. 20%, respectively. When analyzing ATAb levels over time, patients with a persistent ATAb level above the median had a higher OS (HR = 0.41 [0.19-0.89], p = 0.025) and PFS (HR = 0.54 [0.31-0.95], p = 0.032) compared with patients with a persistent ATAb level below the median. Patients whose ATAb levels increased above the median during treatment had an improved OS (HR = 0.27 [0.06-1.22], p = 0.088) and PFS (HR = 0.24 [0.07-0.77], p = 0.017) compared with patients whose ATAb levels decreased below the median. Conclusions: Acquired overt thyroid toxicity and above median ATAb levels during anti-PD-1 treatment are associated with improved PFS and OS. In addition, our results suggest that ATAb levels at baseline are of clinical relevance for PFS and OS.

• Authors: Edwin A Basak, Jan W M van der Meer, Daan P Hurkmans, Marco W J Schreurs, Esther Oomen-de Hoop, Astrid A M van der Veldt, Sander Bins, Arjen Joosse, Stijn L W Koolen, Reno Debets, Robin P Peeters, Joachim G J V Aerts, Ron H J Mathijssen, Marco Medici
• Journal: Thyroid : official journal of the American Thyroid Association (Thyroid) Vol. 30 Issue 7 Pg. 966-973 (07 2020) ISSN: 1557-9077 [Electronic] United States
• PMID: 32151195 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents, Immunological
• Autoantibodies
• Immune Checkpoint Inhibitors
• Nivolumab
• pembrolizumab

Topics

• Aged
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Antineoplastic Agents, Immunological (therapeutic use)
• Autoantibodies (immunology)
• Carcinoma, Non-Small-Cell Lung (drug therapy, immunology, pathology)
• Carcinoma, Renal Cell (drug therapy, immunology, pathology)
• Female
• Humans
• Immune Checkpoint Inhibitors (therapeutic use)
• Immunotherapy
• Kidney Neoplasms (drug therapy, immunology, pathology)
• Lung Neoplasms (drug therapy, immunology, pathology)
• Male
• Melanoma (drug therapy, immunology, pathology)
• Middle Aged
• Nivolumab (therapeutic use)
• Prognosis
• Skin Neoplasms (drug therapy, immunology, pathology)
• Thyroid Gland (immunology, physiopathology)
• Treatment Outcome